Atorvastatin added to interferon β for relapsing multiple sclerosis: a randomized controlled trial.

Area of Science:

• Neuroimmunology
• Pharmacology
• Clinical Trials

Background:

• Statins possess anti-inflammatory and immunomodulatory properties beyond lipid reduction.
• Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
• Interferon beta-1b is a standard treatment for relapsing-remitting MS.

Purpose of the Study:

• To evaluate the efficacy of atorvastatin as an add-on therapy to interferon beta-1b in patients with relapsing-remitting MS.
• To assess the impact of atorvastatin on new lesion formation and disease activity over 12 months.

Main Methods:

• A multicenter, randomized, parallel-group, rater-blinded study involving 77 patients with relapsing-remitting MS.
• Patients received interferon beta-1b, then were randomized to atorvastatin 40 mg/day or placebo for 12 months.
• Primary endpoint: proportion of patients with new T2 lesions at month 15. Secondary endpoints included lesion volume, brain volume, and clinical outcomes.

Main Results:

• No significant difference in the proportion of patients with new T2 lesions between the atorvastatin and placebo groups (OR 1.14; p=0.81).
• Secondary endpoints, including lesion load, brain volume changes, and relapse rates, also showed no significant differences between groups.
• Transient elevations in liver enzymes were more frequent in the atorvastatin group (p=0.02).

Conclusions:

• Atorvastatin 40 mg/day added to interferon beta-1b did not demonstrate a beneficial effect in relapsing-remitting MS over 12 months.
• The combination therapy did not reduce new lesion formation or impact other disease markers compared to interferon beta-1b monotherapy.
• Further research may be needed to explore statin effects in MS, but this specific combination showed no added benefit.